

Monash Investors Small Companies Trust

Hedge Fund (ASX : MAAT)



High Conviction
Fund



Australian Small
Companies



Proven Track
Record¹



Buy and Sell on
the ASX or direct

October 2023 Fund Update

October was the third consecutive month of market declines, and the worst of the three. The S&P/ASX Small Ords was down 5.5% for the month and 10.5% for the three months. After fees the Fund fell 9.8% for the month and 11.8% for the three months. At the time of writing the Fund is up 5.1% so far this month, which is ahead of the market.

Our portfolio is not usually so sensitive to falls in the market, and our long term record remains strong. Apart from it being a weak month for the market, and growth stocks in particular, in October two of our larger holdings cost us 4% collectively. Both the falls were unrelated to their current business activity.

Impedimed (ASX: IPD) fell 34%. It sells a medical device which has become the standard of care in the USA to monitor post-operative cancer patients for lymphedema. It is in the early stage of its product roll out and making good progress.

Ironically, the fall was due to the success of a board spill that was driven by private and institutional investors who wanted a board more focused on costs as well as growth, in order to improve shareholder returns.

Four independent directors were replaced with four new independent directors and the new Chairman is the ex CFO of Nanosonics. Nothing problematic occurred at an operational level, management has welcomed the new Board and it has a strong balance sheet. Our valuation of the stock is well in excess of double the current share price. Impedimed's share price has recovered 22% since the beginning of November.

Telix (ASX: TLX) fell 22%. We first invested in Telix at the equivalent of \$0.17 per share 7 years ago, and the stock has had multiple 20% drawdowns on its way to \$9.20 today. It sells radiopharmaceuticals for cancer patients. It is a cash

¹ Inception date is 28 May 2021. Past performance is not indicative of future performance.

Return Summary¹ (after all fees)

1 Month	3 Months
-9.8%	-11.8%
1 Year	Since Inception
-12.8%	-5.8% _{pa}



Our Investment team: Sebastian Correia, Simon Shields and Shane Fitzgerald

This fund is appropriate for investors with "High" and "Very High" risk and return profiles. A suitable investor for this fund is prepared to accept high risk in the pursuit of capital growth with a medium to long investment timeframe. Investors should refer to the [TMD](#) for further information.

Monash Investors Small Companies Trust

Hedge Fund (ASX : MAAT)

flow positive business with sales already over \$500m pa for its prostate cancer imaging product and growing strongly.

Telix's drugs may also be used to treat cancer using higher doses of radiation. Last month it released the results of its Phase 1 study for a potential prostate therapy drug.

The trial successfully met its endpoints however there was a lower reduction in patient PSA levels observed than for competing products. The market reacted as if this would be an indicator of how effective the drug would be and the share price fell.

This will likely be an incorrect assumption as the Telix drug applies a lower dose than competitors but previous studies have shown it results in better patient survival.

This raises the question as to why the drug gave a lower PSA reduction but a much better survivability. The likely answer is

that TLX is using an antibody instead of small molecule used by the other drugs. Antibodies are retained in the body longer allowing the radioisotope to have greater effect. Proving this is what phases two and three of trial will be about.

We are confident that Telix's business operations more than justify the current share price, and that its pipeline of imaging and therapy products will result in a high pay-off to investors. Telix's share price has recovered 8% since the beginning of November.

Despite the outsized level of volatility in these two stocks, their outlook over the next few years is strong with our valuations for both stocks well above 60% upside from here.

The Fund's major exposures are to Healthcare, Consumer Discretionary, Energy (via Uranium), and IT.

Return Summary Since Inception (after fees)²

	MAAT	Small Ords
CYTD	-9.88%	-6.05%
FYTD	-11.33%	-7.28%
1 month	-9.80%	-5.45%
3 Month	-11.82%	-10.45%
6 Month	-14.27%	-10.28%
1 Year	-12.77%	-5.10%
2 Years pa	-11.34%	-11.95%
Since Inception pa	-5.77%	-7.23%

Return Summary Since Inception (after fees)²

	MAIF	Small Ords
CYTD	-8.67%	-6.05%
FYTD	-10.45%	-7.28%
1 month	-9.52%	-5.45%
3 Month	-10.96%	-10.45%
6 Month	-13.69%	-10.28%
1 Year	-11.74%	-5.10%
2 Years pa	-10.50%	-11.95%
3 Years pa	2.43%	0.52%
4 Years pa	4.30%	-0.22%
5 Years pa	8.23%	2.55%
7 Years pa	5.24%	4.19%
Since Inception pa	8.33%	4.72%

²Due to lack of MAAT history, data from Monash Small Companies Fund (MAIF) (inception date 2 July 2012) has been used. Glossary of terms can be found on the Fund's website at www.monashinvestors.com/glossary/

Monash Investors Small Companies Trust

Hedge Fund (ASX : MAAT)

For MAAT Unit Registry enquiries, please contact

Apex Fund Services Pty Limited
P: 1300 133 451 (in Australia)
+61 2 8259 8888 (international)
E: registry@apexgroup.com

For all business development enquiries, please contact

Cameron Harris
P: +61 400 248 435
cameron@gsmcapital.com.au

For more information about MAAT and the strategy, please refer to the Monash Investors website at www.monashinvestors.com. You can also [follow us on Livewire here](#) or [subscribe to our updates here](#)

This document is prepared by Monash Investors Pty Limited ABN 67 153 180 333, AFSL 417 201 ("Monash Investors") as authorised representatives of Sanlam Private Wealth Pty Ltd ABN 18 136 960 775, AFSL 337 927 ("Sanlam") for the provision of general financial product advice in relation to the Monash Investors Small Companies Trust (Hedge Fund) ARSN 642 280 331 ("Fund") and authorised for release by The Trust Company (RE Services) Limited ABN 45 003 278 831, AFSL 235 150 ("Perpetual") as the responsible entity of, and issuer of units in the Fund. Monash Investors is the investment manager of the Fund. A Product Disclosure Statement ("PDS") dated 17 July 2023 together with a Target Market Determination ("TMD"), both issued by Perpetual, is available for the Fund at www.monashinvestors.com. You should obtain and consider the PDS and TMD for the Fund before deciding whether to acquire, or continue to hold, an interest in the Fund. The information provided is general information only and is not intended to provide you with financial advice, it does not consider your investment objectives, financial situation or particular needs. You should consider your own investment objectives, financial situation and particular needs before acting upon any information provided and consider seeking advice from a financial advisor if necessary. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. No company in Perpetual Group (Perpetual Limited ABN 86 000 431 827 and its subsidiaries) guarantees the performance of any fund or the return of an investor's capital.

You should not base an investment decision simply on past performance. Past performance is not a reliable indicator of future performance. Returns are not guaranteed and so the value of an investment may rise or fall. Total returns shown have been calculated using NAV prices after taking into account all ongoing fees and assuming reinvestment of distribution. No allowance has been made for taxation. Comparisons are provided for information purposes only and are not a direct comparison against benchmarks or indices that have the same characteristics as the Fund. Reference to Target Distributions, is a target return only. There is no guarantee the Fund will meet its investment objective. The payment of a quarterly distribution is a goal of the Fund only and neither Monash Investors or Perpetual provide any representations or warranty (whether express or implied) in relation to the payment of any quarterly cash income. The Fund reserves the discretion to amend its distribution policy.

The rating contained in this document is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person's particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.